ArticleDiscover oncology2026
A novel model for assessing lymph node metastasis and the immune microenvironment in breast cancer by integrating digital pathology images and transcriptomics.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND/
aimsAccurate prediction of the lymph node status is essential for clinical decision-making in breast cancer. This work aimed to develop a multimodal deep learning model that integrates gene expression data with hematoxylin and eosin (H&E)-stained whole slide images (WSIs) to predict lymph node metastasis (LNM) and assess the tumor microenvironment in breast cancer.
methodsThe Cancer Genome Atlas (TCGA) database was used to gather the clinicopathological data, transcriptome information, and WSIs of patients with breast cancer. WSIs from Xuzhou Central Hospital were used as external validations. Four deep learning models were used to build the LNM pathological model. The pathogenic model and hub genes provided the foundation for constructing the nomogram. The potential mechanism was evaluated through the performance of functional enrichment. The calibration, discrimination, and clinical usefulness of the pathological model, multi-gene model, and nomogram were evaluated. Furthermore, the correlation between the nomogram and prognosis, clinicopathological features, and the quantity of immune cells was evaluated. Using immunohistochemistry and popliteal lymph node metastasis tests, the expression of beta-1,3-galactosyltransferase-4 (B3GALT4) in tumor tissues and its association with LNM and CD8
resultsThe findings of the present study demonstrated that in comparison to any single model, the nomogram's area under the curve (AUC) was better, at 0.99 [95% CI: 0.98-1.00]. The calibration curve demonstrated a high degree of agreement. The bulk of the threshold probabilities in this model were linked to favorable net benefits. Compared to the low-risk group, patients with high-risk breast cancer had more CD8
conclusionsThis model may provide a higher predictive value for LNM. B3GALT4 could serve as a risk biomarker of lymph node metastatic breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.